- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Rhenman & Partners Asset Management AB Boosts Biogen Stake by 358%
The investment firm now owns $7.7 million in shares of the biotechnology company.
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
Rhenman & Partners Asset Management AB, an investment firm, increased its stake in Biogen Inc. (NASDAQ:BIIB) by 358.3% in the third quarter of 2025, according to a recent 13F filing. The firm now owns 55,000 shares of the biotechnology company's stock, valued at $7.7 million.
Why it matters
Biogen is a major player in the biotechnology industry, particularly in the areas of neurology and neurodegenerative diseases. The significant increase in Rhenman & Partners' investment in the company suggests the firm sees long-term potential in Biogen's pipeline and business prospects.
The details
According to the 13F filing, Rhenman & Partners Asset Management AB acquired an additional 43,000 shares of Biogen during the third quarter, bringing its total position to 55,000 shares. This represents a 358.3% increase in the firm's stake in the biotechnology company.
- Rhenman & Partners Asset Management AB increased its Biogen stake in the 3rd quarter of 2025.
The players
Rhenman & Partners Asset Management AB
An investment firm that manages assets on behalf of clients.
Biogen Inc.
A multinational biotechnology company focused on developing therapies for neurological and neurodegenerative diseases.
The takeaway
Rhenman & Partners' significant increase in its Biogen stake suggests the firm sees long-term value in the biotechnology company's pipeline and business prospects, which could be a positive sign for Biogen's future performance.
